<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04973564</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-02T05:11:53+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity</title>
            <author role="aut">
              <persName>
                <forename type="first">Marie-Noëlle</forename>
                <surname>Paludetto</surname>
              </persName>
              <idno type="halauthorid">1478185-0</idno>
              <affiliation ref="#struct-511697"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Florent</forename>
                <surname>Puisset</surname>
              </persName>
              <email type="md5">6c8e8223c41845f2dd6b3eae84851132</email>
              <email type="domain">iuct-oncopole.fr</email>
              <idno type="idhal" notation="string">florent-puisset</idno>
              <idno type="idhal" notation="numeric">1443946</idno>
              <idno type="halauthorid" notation="string">1478186-1443946</idno>
              <affiliation ref="#struct-511697"/>
              <affiliation ref="#struct-450027"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Etienne</forename>
                <surname>Chatelut</surname>
              </persName>
              <idno type="halauthorid">184454-0</idno>
              <affiliation ref="#struct-511697"/>
              <affiliation ref="#struct-300150"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Cécile</forename>
                <surname>Arellano</surname>
              </persName>
              <email type="md5">efde68a7d3d8172c2aa6389d3230b527</email>
              <email type="domain">univ-tlse3.fr</email>
              <idno type="idhal" notation="string">cecile-arellano</idno>
              <idno type="idhal" notation="numeric">1216808</idno>
              <idno type="halauthorid" notation="string">491176-1216808</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-5667-9153</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-6336-7158</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Marie‐noëlle</forename>
                <surname>Paludetto</surname>
              </persName>
              <idno type="halauthorid">3399745-0</idno>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Florent</forename>
                <surname>Puisset</surname>
              </persName>
              <email type="md5">6c8e8223c41845f2dd6b3eae84851132</email>
              <email type="domain">iuct-oncopole.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2025-03-03 10:33:39</date>
              <date type="whenModified">2026-02-07 05:30:32</date>
              <date type="whenReleased">2025-03-03 10:33:39</date>
              <date type="whenProduced">2019-05-20</date>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="1626350">
                <persName>
                  <forename>Florent</forename>
                  <surname>Puisset</surname>
                </persName>
                <email type="md5">6c8e8223c41845f2dd6b3eae84851132</email>
                <email type="domain">iuct-oncopole.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04973564</idno>
            <idno type="halUri">https://hal.science/hal-04973564</idno>
            <idno type="halBibtex">paludetto:hal-04973564</idno>
            <idno type="halRefHtml">&lt;i&gt;Medicinal Research Reviews&lt;/i&gt;, 2019, 39 (6), pp.2105-2152. &lt;a target="_blank" href="https://dx.doi.org/10.1002/med.21577"&gt;&amp;#x27E8;10.1002/med.21577&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Medicinal Research Reviews, 2019, 39 (6), pp.2105-2152. &amp;#x27E8;10.1002/med.21577&amp;#x27E9;</idno>
            <availability status="restricted"/>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="UNIV-TLSE3">Université de Toulouse</idno>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-UT3">Université Toulouse 3</idno>
            <idno type="stamp" n="UT3-INP">Université de Toulouse / Toulouse INP</idno>
            <idno type="stamp" n="UT3-TOULOUSEINP">Université de Toulouse / Toulouse INP</idno>
            <idno type="stamp" n="CRCT">CRCT</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Marie-Noëlle</forename>
                    <surname>Paludetto</surname>
                  </persName>
                  <idno type="halauthorid">1478185-0</idno>
                  <affiliation ref="#struct-511697"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Florent</forename>
                    <surname>Puisset</surname>
                  </persName>
                  <email type="md5">6c8e8223c41845f2dd6b3eae84851132</email>
                  <email type="domain">iuct-oncopole.fr</email>
                  <idno type="idhal" notation="string">florent-puisset</idno>
                  <idno type="idhal" notation="numeric">1443946</idno>
                  <idno type="halauthorid" notation="string">1478186-1443946</idno>
                  <affiliation ref="#struct-511697"/>
                  <affiliation ref="#struct-450027"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Etienne</forename>
                    <surname>Chatelut</surname>
                  </persName>
                  <idno type="halauthorid">184454-0</idno>
                  <affiliation ref="#struct-511697"/>
                  <affiliation ref="#struct-300150"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Cécile</forename>
                    <surname>Arellano</surname>
                  </persName>
                  <email type="md5">efde68a7d3d8172c2aa6389d3230b527</email>
                  <email type="domain">univ-tlse3.fr</email>
                  <idno type="idhal" notation="string">cecile-arellano</idno>
                  <idno type="idhal" notation="numeric">1216808</idno>
                  <idno type="halauthorid" notation="string">491176-1216808</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-5667-9153</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-6336-7158</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Marie‐noëlle</forename>
                    <surname>Paludetto</surname>
                  </persName>
                  <idno type="halauthorid">3399745-0</idno>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">17004</idno>
                <idno type="issn">0198-6325</idno>
                <idno type="eissn">1098-1128</idno>
                <title level="j">Medicinal Research Reviews</title>
                <imprint>
                  <publisher>Wiley</publisher>
                  <biblScope unit="volume">39</biblScope>
                  <biblScope unit="issue">6</biblScope>
                  <biblScope unit="pp">2105-2152</biblScope>
                  <date type="datePub">2019-05-20</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1002/med.21577</idno>
              <idno type="pubmed">31111528</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">tyrosine kinase inhibitors</term>
                <term xml:lang="en">structural alerts</term>
                <term xml:lang="en">reactive drug metabolites</term>
                <term xml:lang="en">mechanism-based inhibitions</term>
                <term xml:lang="en">drug-induced liver injury</term>
                <term xml:lang="en">drug-drug interactions</term>
                <term xml:lang="en">cytochromes P450</term>
              </keywords>
              <classCode scheme="mesh">Animals</classCode>
              <classCode scheme="mesh">Chemical and Drug Induced Liver Injury</classCode>
              <classCode scheme="mesh">Cytochrome P-450 Enzyme System</classCode>
              <classCode scheme="mesh">Drug Interactions</classCode>
              <classCode scheme="mesh">Glucuronosyltransferase</classCode>
              <classCode scheme="mesh">Humans</classCode>
              <classCode scheme="mesh">Protein Kinase Inhibitors</classCode>
              <classCode scheme="mesh">Time Factors</classCode>
              <classCode scheme="halDomain" n="sdv.sp.pharma">Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Abstract Tyrosine kinase inhibitors (TKI) are small heterocyclic molecules targeting transmembrane and cytoplasmic tyrosine kinases that have met with considerable success in clinical oncology. TKI are associated with toxicities including liver injury that may be serious and even life‐threatening. Many of them require warnings in drug labeling against liver injury, and five of them have Black Box Warning (BBW) labels. Although drug‐induced liver injury is a matter of clinical and industrial concern, little is known about the underlying mechanisms that likely involve reactive metabolites (RM). RM are electrophiles or radicals originating from the metabolic activation of particular functional groups, known as structural alerts or toxicophores. RM are able to covalently bind to proteins and macromolecules, causing cellular damage and even cell death. If the adducted protein is the enzyme involved in RM formation, time‐dependent inhibition of the enzyme—also called mechanism‐based inhibition (MBI) or inactivation—can occur and lead to pharmacokinetic drug‐drug interactions. To mitigate RM liabilities, common practice in drug development includes avoiding structural alerts and assessing RM formation via RM trapping screens with soft and hard nucleophiles (glutathione, potassium cyanide, and methoxylamine) in liver microsomes. RM‐positive derivatives are further optimized to afford drug candidates with blocked or minimized bioactivation potential. However, different structural alerts are still commonly used scaffolds in drug design, including in TKI structures. This review focuses on the current state of knowledge of the relations among TKI structures, bioactivation pathways, RM characterization, and hepatotoxicity and cytochrome P450 MBI in vitro.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-511697" status="OLD">
          <idno type="IdRef">168095661</idno>
          <idno type="ISNI">0000000477733907</idno>
          <idno type="RNSR">201119444S</idno>
          <idno type="ROR">https://ror.org/003412r28</idno>
          <orgName>Centre de Recherches en Cancérologie de Toulouse</orgName>
          <orgName type="acronym">CRCT</orgName>
          <date type="start">2011-01-01</date>
          <date type="end">2025-01-01</date>
          <desc>
            <address>
              <addrLine>Centre de Recherches en Cancérologie de Toulouse2 Avenue Hubert Curien31037 Toulouse Cedex 1FRANCE</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.crct-inserm.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-217752" type="direct"/>
            <relation active="#struct-443875" type="indirect"/>
            <relation name="U1037" active="#struct-303623" type="direct"/>
            <relation name="UMR5071 / ERL5294" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="regrouplaboratory" xml:id="struct-450027" status="OLD">
          <idno type="ROR">https://ror.org/014hxhm89</idno>
          <orgName>Institut Universitaire du Cancer de Toulouse - Oncopole</orgName>
          <orgName type="acronym">IUCT Oncopole - UMR 1037</orgName>
          <desc>
            <address>
              <addrLine>Av. Irène Joliot-Curie 31100 Toulouse</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-217752" type="direct"/>
            <relation active="#struct-443875" type="indirect"/>
            <relation active="#struct-300075" type="direct"/>
            <relation active="#struct-303623" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-300150" status="VALID">
          <orgName>Oncopole Claudius Regaud</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-1673976" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-217752" status="OLD">
          <idno type="IdRef">026404672</idno>
          <idno type="ISNI">0000000121617331</idno>
          <idno type="ROR">https://ror.org/02v6kpv12</idno>
          <idno type="Wikidata">Q1273188</idno>
          <orgName>Université Toulouse III - Paul Sabatier</orgName>
          <orgName type="acronym">UT3</orgName>
          <date type="end">2025-01-01</date>
          <desc>
            <address>
              <addrLine>118 route de Narbonne - 31062 Toulouse</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-tlse3.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-443875" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-443875" status="VALID">
          <idno type="ROR">https://ror.org/017tgbk05</idno>
          <orgName>Communauté d'universités et établissements de Toulouse</orgName>
          <orgName type="acronym">Comue de Toulouse</orgName>
          <desc>
            <address>
              <addrLine>41 Allée Jules Guesde, 31000 Toulouse</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.univ-toulouse.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-300075" status="VALID">
          <orgName>Centre Hospitalier Universitaire de Toulouse</orgName>
          <orgName type="acronym">CHU Toulouse</orgName>
          <desc>
            <address>
              <addrLine>regroupe les hôpitaux  Purpan, Rangueil, Pierre-Paul Riquet, Larey, Paule de Viguier, Hôtel Dieu Saint-Jacques, La Grave, etc.</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.chu-toulouse.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-1673976" status="VALID">
          <orgName>IUCT Oncopole</orgName>
          <desc>
            <address>
              <addrLine>Av. Irène Joliot-Curie 31100 Toulouse</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.iuct-oncopole.fr</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>